M
any physicians consider triplenegative breast cancer (TNBC) the most difficult type to treat, and some patients think it is a death sentence. This subtype of breast cancer is extremely aggressive, has limited treatment options, and carries a high risk of recurrence and death. Unlike breast cancers that express hormone receptors for estrogen and/or progesterone and overex press the HER-2/ neu protein, TNBC is negative for all three proteins, so it cannot be treated with drugs specifically targeted at them. 
Vaccines
PARP inhibitors, although furthest along in the pipeline, are not the whole story. One alternative strategy is to target TNBC with therapeutic vaccines. Andrew Simpson, Ph.D., scientifi c director of the Ludwig Institute for Cancer Therapy, New York, and colleagues reported in July in the Proceedings of the National Academy of Sciences that CT-X genes, which are normally expressed only in germ cell development, are expressed in TNBC. One of them in particular, called MAGEA3, is expressed in about 40% of women with TNBC. Because MAGEA3 is not active in the adult female body, but "turned on" only in cancer, it is an excellent target for a therapeutic vaccine, Simpson said.
Vaccines targeted at the MAGEA3 gene product, which is also known to be expressed in lung cancer and melanoma, are now being tested in phase II and phase III studies, respectively, by GlaxoSmithKline. "We therefore hope to persuade the company to conduct trials in TNBC," Simpson said.
Another candidate target of an immunotherapeutic vaccine is the MUC-1 antigen, which is expressed in the vast majority of breast cancers, including TNBC, as well as in ovarian, lung, and prostate malignancies. A MUC-1 vaccine developed by University of Pittsburgh researchers is also being tested in pancreatic and prostate cancers. Working with them, Baar has developed a vaccine based on this antigen, which will begin testing later this year in earlystage TNBC patients following primary therapy with surgery, radiation and chemotherapy. In the new study, Baar will vaccinate up to 37 early-stage patients up to six times in order to raise an immune response against MUC-1. His aim is to eventually develop the vaccine as a long-term preventive therapy for TNBC. "We want to determine if it is possible to reduce relapse for women with TNBC who have completed primary treatment but who have a high risk of recurrence," he said.
More Targets

